Eli Lilly Opposes Trump Administration's Drug Pricing Law

Eli Lilly, a major pharmaceutical company, has publicly opposed the Trump administration's initiative to codify "most favored nation" (MFN) drug pricing into law. This stance was articulated by CEO Dave Ricks during an interview with CNBC, highlighting the company's concerns regarding the implications of such legislation.

CNBC

The MFN pricing model aims to align U.S. drug prices with those in other wealthy nations, a concept that President Donald Trump has championed. The administration's rationale is that American consumers currently bear the burden of higher prices, which subsidize lower costs abroad. In 2025, Eli Lilly, along with over a dozen other drug manufacturers, entered agreements with the Trump administration to charge prices in the U.S. that are comparable to those in other countries, believing this would alleviate concerns over drug pricing.

CNBC

In his interview, Dave Ricks expressed that Eli Lilly's opposition stems from apprehensions about the potential consequences of codifying MFN pricing. He indicated that the company had anticipated that the agreements made with the administration would mitigate the push for legislative action. The White House, however, has been actively seeking to solidify these pricing structures through Congress, despite not publicly releasing the draft text of the proposed legislation.

CNBC

Critics within the pharmaceutical industry, including Eli Lilly, argue that codifying MFN pricing could lead to unintended consequences, such as reduced investment in drug development and innovation. They contend that while the intention behind the MFN model is to lower costs for consumers, it may ultimately hinder the availability of new treatments and therapies.

CNBC

While Eli Lilly's opposition is clear, the full scope of the pharmaceutical industry's response to the MFN pricing initiative remains uncertain. The lack of publicly available draft text for the proposed legislation leaves room for speculation regarding its specific provisions and potential impacts on drug pricing and availability.

CNBC

As the Trump administration continues to push for the codification of MFN drug pricing, the pharmaceutical industry is likely to engage in further discussions and negotiations with lawmakers. The outcome of these efforts could significantly shape the future landscape of drug pricing in the United States.

CNBC

“Eli Lilly opposes the White House's push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said in an interview with CNBC.” — Dave Ricks, CEO of Eli Lilly

CNBC

“The pharmaceutical industry thought the agreements would pacify those concerns and thwart attempts to make "most favored nation" pricing the law.” — Dave Ricks, CEO of Eli Lilly

CNBC